FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023763630> ?p ?o ?g. }

• W2023763630 abstract "[Introduction] Aromatase inhibitors (AI) are the common treatment for postmenopausal estrogen receptor (ER)-positive breast cancer. However, some patients acquire resistance to AI. To investigate the mechanism of resistance, we have established several breast cancer cell lines as AI-resistant models. Recently, we have reported on AMD-EDR cells (androgen metabolite-dependent and estrogen-depletion-resistant cells) derived from MCF-7, in which ER activity depends on one of the androgen metabolites. In this study, another AI-resistant mechanism was shown by T-47D-derived AI-resistant cells, indicating the character of the AI-resistant models differ with their parental cells. [Methods] T-47D was cultured under estrogen-depleted and androgen-supplemented conditions for more than 3 months, simulating the AI treatment, which resulted in two stable variant cell lines. To examine the response of variant cell lines to estrogen and androgen, cell proliferation assay and luciferase reporter assay were performed. The mRNA and protein levels were measured by real-time PCR and western blotting. To identify the elements promoting the AI-resistance mechanism in the variant cell lines, the gene expression of variant cell line was compared with that of T-47D by microarray analysis. Immunohistchemical staining for AR and PSA was performed on 20 pairs of primary and recurrent tissue samples from AI-resistant breast cancer. [Results] The variant cell lines had neither growth response to estrogen nor expression of ER. On the other hand, androgen markedly induced the proliferation of these cell lines, and this effect was inhibited by the androgen receptor (AR) antagonist, bicalutamide. Increased expression of AR and androgen-responsive genes in the variant cell lines indicated that the AR-dependent growth pathway was enhanced. Moreover, L-dopa decarboxylase (DDC), an AR coactivator, was extremely induced, suggesting it is an enhancer of AR activity in the variant cell lines. Immunohistochemistry analysis revealed that all primary tumors did not express PSA, while two recurrent tumors did express PSA, suggesting that AR transcriptional activity is enhanced in some AI-resistant breast cancers. [Conclusion] During the AI treatment simulation these variant cell lines transformed from ER-dependent to AR-dependent, and overexpression of AR and DDC possibly enhanced the AR-mediated proliferative pathway. PSA-expression in the AI-resistance recurrent tumors suggests that AR-mediated pathway possibly plays a role in aromatase inhibitor-resistance mechanism. The AI-resistance mechanism in T-47D-derived variant cell lines was different from that in MCF-7-derived AMR-EDR cells. The fact that the character of the AI-resistant models differed with their parental cells supports the hypothesis that the intristic character of individual primary tumors contributes to diversification of AI-resistance mechanisms. Citation Format: Rika Fujii, Toru Hanamura, Toshifumi Niwa, Yuri Yamaguchi, Takanori Ishida, Hironobu Sasano, Noriaki Ohuchi, Shin-ichi Hayashi. Androgen receptor acquires an oncogenic role in the AI resistance mechanism in breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4754. doi:10.1158/1538-7445.AM2014-4754" @default.
• W2023763630 created "2016-06-24" @default.
• W2023763630 creator A5003956323 @default.
• W2023763630 creator A5015575554 @default.
• W2023763630 creator A5027651565 @default.
• W2023763630 creator A5029697081 @default.
• W2023763630 creator A5038484790 @default.
• W2023763630 creator A5051897132 @default.
• W2023763630 creator A5053254171 @default.
• W2023763630 creator A5080186649 @default.
• W2023763630 date "2014-09-30" @default.
• W2023763630 modified "2023-09-26" @default.
• W2023763630 title "Abstract 4754: Androgen receptor acquires an oncogenic role in the AI resistance mechanism in breast cancer" @default.
• W2023763630 doi "https://doi.org/10.1158/1538-7445.am2014-4754" @default.
• W2023763630 hasPublicationYear "2014" @default.
• W2023763630 type Work @default.
• W2023763630 sameAs 2023763630 @default.
• W2023763630 citedByCount "0" @default.
• W2023763630 crossrefType "proceedings-article" @default.
• W2023763630 hasAuthorship W2023763630A5003956323 @default.
• W2023763630 hasAuthorship W2023763630A5015575554 @default.
• W2023763630 hasAuthorship W2023763630A5027651565 @default.
• W2023763630 hasAuthorship W2023763630A5029697081 @default.
• W2023763630 hasAuthorship W2023763630A5038484790 @default.
• W2023763630 hasAuthorship W2023763630A5051897132 @default.
• W2023763630 hasAuthorship W2023763630A5053254171 @default.
• W2023763630 hasAuthorship W2023763630A5080186649 @default.
• W2023763630 hasConcept C121608353 @default.
• W2023763630 hasConcept C126322002 @default.
• W2023763630 hasConcept C134018914 @default.
• W2023763630 hasConcept C172313692 @default.
• W2023763630 hasConcept C2776166826 @default.
• W2023763630 hasConcept C2777164284 @default.
• W2023763630 hasConcept C2777911890 @default.
• W2023763630 hasConcept C2780192828 @default.
• W2023763630 hasConcept C502942594 @default.
• W2023763630 hasConcept C530470458 @default.
• W2023763630 hasConcept C54355233 @default.
• W2023763630 hasConcept C55493867 @default.
• W2023763630 hasConcept C61367390 @default.
• W2023763630 hasConcept C62112901 @default.
• W2023763630 hasConcept C71315377 @default.
• W2023763630 hasConcept C71924100 @default.
• W2023763630 hasConcept C81885089 @default.
• W2023763630 hasConcept C84606932 @default.
• W2023763630 hasConcept C86803240 @default.
• W2023763630 hasConceptScore W2023763630C121608353 @default.
• W2023763630 hasConceptScore W2023763630C126322002 @default.
• W2023763630 hasConceptScore W2023763630C134018914 @default.
• W2023763630 hasConceptScore W2023763630C172313692 @default.
• W2023763630 hasConceptScore W2023763630C2776166826 @default.
• W2023763630 hasConceptScore W2023763630C2777164284 @default.
• W2023763630 hasConceptScore W2023763630C2777911890 @default.
• W2023763630 hasConceptScore W2023763630C2780192828 @default.
• W2023763630 hasConceptScore W2023763630C502942594 @default.
• W2023763630 hasConceptScore W2023763630C530470458 @default.
• W2023763630 hasConceptScore W2023763630C54355233 @default.
• W2023763630 hasConceptScore W2023763630C55493867 @default.
• W2023763630 hasConceptScore W2023763630C61367390 @default.
• W2023763630 hasConceptScore W2023763630C62112901 @default.
• W2023763630 hasConceptScore W2023763630C71315377 @default.
• W2023763630 hasConceptScore W2023763630C71924100 @default.
• W2023763630 hasConceptScore W2023763630C81885089 @default.
• W2023763630 hasConceptScore W2023763630C84606932 @default.
• W2023763630 hasConceptScore W2023763630C86803240 @default.
• W2023763630 hasLocation W20237636301 @default.
• W2023763630 hasOpenAccess W2023763630 @default.
• W2023763630 hasPrimaryLocation W20237636301 @default.
• W2023763630 hasRelatedWork W1664987578 @default.
• W2023763630 hasRelatedWork W1969154275 @default.
• W2023763630 hasRelatedWork W2010080966 @default.
• W2023763630 hasRelatedWork W2047276289 @default.
• W2023763630 hasRelatedWork W2094325536 @default.
• W2023763630 hasRelatedWork W2308811910 @default.
• W2023763630 hasRelatedWork W2374915992 @default.
• W2023763630 hasRelatedWork W2407656906 @default.
• W2023763630 hasRelatedWork W2488976767 @default.
• W2023763630 hasRelatedWork W2489291602 @default.
• W2023763630 hasRelatedWork W2594560715 @default.
• W2023763630 hasRelatedWork W2729944130 @default.
• W2023763630 hasRelatedWork W2740097508 @default.
• W2023763630 hasRelatedWork W2765464895 @default.
• W2023763630 hasRelatedWork W2766497722 @default.
• W2023763630 hasRelatedWork W2792133745 @default.
• W2023763630 hasRelatedWork W2810639406 @default.
• W2023763630 hasRelatedWork W2944015698 @default.
• W2023763630 hasRelatedWork W2953536971 @default.
• W2023763630 hasRelatedWork W2740874893 @default.
• W2023763630 isParatext "false" @default.
• W2023763630 isRetracted "false" @default.
• W2023763630 magId "2023763630" @default.
• W2023763630 workType "article" @default.